Research progress in immune checkpoint inhibitors in the treatment of oncogenedriven advanced nonsmall cell lung cancer / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
; (12): 418-425, 2020.
Article
in En
| WPRIM
| ID: wpr-827425
Responsible library:
WPRO
ABSTRACT
The clinical application of immune checkpoint inhibitors (ICIs) lead to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer (NSCLC), but the efficacy of ICIs in oncogene-driven NSCLC is controversial. Existing research shows that the efficacy of ICIs may be related to different types of driver genes, programmed cell death-ligand 1 (PD-L1) level, and tumor mutational burden (TMB). It may involved in other factors, such as clinical characteristics, and immune cell density. ICIs monotherapy or combination therapy may play a role in a subset of oncogene-driven NSCLC patients, but further studies are needed to select these patients, which may be an important direction for the future development of advanced NSCLC.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Biomarkers, Tumor
/
Carcinoma, Non-Small-Cell Lung
/
Drug Therapy
/
B7-H1 Antigen
/
Genetics
/
Immunotherapy
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Journal of Central South University(Medical Sciences)
Year:
2020
Type:
Article